Acesion Pharma is a Danish biotech company focused on the development of innovative treatments for atrial fibrillation and other cardiac rhythm disorders. The company's lead candidate, AP30663, is designed to convert atrial fibrillation to sinus rhythm and maintain normal sinus rhythm in patients.

Acesion Pharma is a Danish biotech company founded in 2011. We are aiming to develop more efficacious and safer drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. 
The scientific foundation of Acesion Pharma is the novel concept of treating AF by inhibiting the so-called SK channels. These are ion channels present in the heart where they are relevant for regulating the cardiac rhythm. Blocking this ion channel with a selective drug molecule constitutes a novel and promising target for developing improved treatment of AF.

Novo Holdings

Seed Capital

Wellcome Trust

Acesion Pharma

Acesion Pharma announces today the successful closure of an oversubscribed €45 million Series B Financing Round. Co-led by Canaan and Alpha Wave Global, LP, along with the support of the Global BioAccess Fund and existing investor Novo Holdings, the investment marks a significant leap forward in our mission to advance novel therapies for atrial fibrillation (AF).
 
With the capital raised, we are able to progress AP31969, our SK ion channel inhibitor tailored for chronic oral AF treatment, through clinical development. This company milestone builds upon strong pre-clinical and recent phase II proof-of-concept data with AP30663, our pioneering SK inhibitor for converting AF to normal sinus rhythm.
 
Read more here: [https://lnkd.in/estqmEm9]

Acesion Pharma is proud to announce the publication of our clinical Phase 2 data in the prestigious Nature Medicine Journal. The trial tested our first-in-class SK ion channel inhibitor AP30663's efficacy in converting Atrial Fibrillation (AF) to normal sinus rhythm with an intravenous infusion. AP30663 achieved a class leading 55% conversion rate resulting in a 99.9% probability of superiority over placebo, demonstrating the first-ever proof of mechanism for SK channel inhibition in AF.
 
In addition, we are pleased to announce the initiation of a Phase 1 trial for AP31969, an oral SK ion channel inhibitor targeting maintenance of sinus rhythm in AF with chronic treatment. We look forward to sharing more updates soon as we continue our work to change the AF treatment landscape. 
 
Read more: https://lnkd.in/du_4bY8Y 
 
#AcesionPharma #AFResearch #CardiacHealth 

On the back of showing clinical proof-of-concept with AP30663, a first-in-class SK channel inhibitor, we have been working hard to progress our second-generation SK channel inhibitor, AP31969 being developed for developed for chronic oral maintenance treatment to prevent atrial fibrillation recurrence.

With AP31969, we aim to solve the major concern with existing drugs; a high-risk of life-threatening cardiac arrhythmia, also known as proarrhythmia and we have generated a strong pre-clinical data package to substantiate this.

Learn more here: https://bit.ly/42Ad1Vf

#atrialfibrillation 

COM:ACESIONPHARMA

Acesion Pharma

Analysis Not Available